
anti-BCMA02 CAR
SP
VL (C11D5.3)
218
linker
VH (C11D5.3)
CD8
hinge
CD8
TM
4-1BB
CD3 ζ

FIGURE 1



Anti-BCMA CAR
Untransduced
Population Doublings
0
2
4
6
8
Day
0
2
4
6
8
10
12
14

FIGURE 2A



VCN
0
1
2
3
4
5
801310
800374
800309
800593
801396
800004
800290
801138
801269
800499
801382

FIGURE 2B



% Anti-BCMA02 CAR Positive
100
80
60
40
20
0
801310
800374
800309
800593
801396
800004
800290
801138
801269
800499
801382

FIGURE 2C



IFN-γ (ng/mL)
0
20
40
60
80
100
801310
800374
800309
800593
801396
800004
800290
801138
801269
800499
801382

FIGURE 2D



Clinical Response Over Time
CRS Grade
tocilizumab Grade 3
tocilizumab Grade 1
tocilizumab Grade 1
tocilizumab Grade 3
tocilizumab Grade 1
tocilizumab, steroids Grade 2
tocilizumab Grade 1
tocilizumab, steroids Grade 2
tocilizumab Grade 1
tocilizumab Grade 1
tocilizumab, steroids Grade 2
none
none
Grade 1
tocilizumab, steroids Grade 2
none
none
Grade 1
15
14
11
21
18
16
13
12
10
9
8
7
20
19
17
6
5
4
3
2
1
0
4
8
12
16
20
24
28
32
36
40
44
48
52
Weeks after bb2121 infusion
* High tumor burden (>50% bone marrow involvement)
Stable Disease
PR
VGPR
CR/sCR
PD
MRD-
† deceased
u = unconfirmed response
Includes unscheduled assessments

FIGURE 3